Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

20.20 +0.29 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 851,910
Open 19.94
Bid (Size) 19.55 (5)
Ask (Size) 20.25 (4)
Prev. Close 19.91
Today's Range 19.92 - 20.24
52wk Range 11.89 - 21.66
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX.
While growth is established for CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), the stock's valuation remains reasonable. 
Via Chartmill
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+18.06%
+18.06%
1 Month
-0.44%
-0.44%
3 Month
+20.60%
+20.60%
6 Month
+31.25%
+31.25%
1 Year
+58.06%
+58.06%

More News

Read More
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:CPRX is showing good growth, while it is not too expensive.
Via Chartmill
A Biotech Breakout Will Be Led By Small Caps
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Via Chartmill
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Via Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Via Benzinga
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
Via Chartmill
Immunome Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.